Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.

Mini Rev Med Chem

Organic Synthesis and Molecular Engineering Lab, Department of Chemistry, National Institute of Technology, Rourkela 769008, India.

Published: March 2022

Severe Acute Respiratory Syndrome (SARS) aka SARS-CoV spread over southern China for the first time in 2002-2003 and history repeated again since last year and took away lives of more than two million people so far. On March 11, 2020 COVID-19 outbreak was officially declared as pandemic by World Health Organization (WHO). The entire world united to fight back against this ultimate destruction. Around 90 vaccines are featured against SARS-CoV-2 and more than 300 active clinical trials are underway by several groups and individuals. So far, no drugs have been currently approved that can completely eliminate the deadly coronavirus. The promising SARS-CoV-2 antiviral drugs are favipiravir, remdesivir, lopinavir, ribavirin and avifavir. In this review, we have discussed the synthetic approaches elaborately made so far by different groups and chemical companies all around the world towards top three convincing anti-viral drugs against SARS-CoV-2, which are favipiravir, remdesivir and lopinavir.

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389557521666210712205655DOI Listing

Publication Analysis

Top Keywords

favipiravir remdesivir
8
remdesivir lopinavir
8
synthetic attempts
4
attempts eminent
4
eminent anti-viral
4
anti-viral candidates
4
candidates sars-cov
4
sars-cov severe
4
severe acute
4
acute respiratory
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!